Takeda Pharmaceutical Co. Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Takeda Pharmaceutical Co. Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Takeda Pharmaceutical Co. Ltd. and its competitors. This provides our Clients with a clear understanding of Takeda Pharmaceutical Co. Ltd. position in the Pharmaceuticals and Biotechnology Industry.

Scope

• The report contains the company’s profile and data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• The SWOT-analysis provides information about the company’s strengths, weaknesses, opportunities, and possible threats against it.
• The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency.
• It also shows the company’s income statement and ratio trend-charts, with balance sheets and cash flows presented on an annual and quarterly basis.
• Company’s financial ratios are directly compared with those of its competitors through industry averages.
• The report provides relevant news, an analysis of PR-activity, and stock price movements.
• The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms.

The benefits of buying the Report are as follows:

• Readers will gain an unrivalled in-depth knowledge about the company.
• The report will help the management of your business environment. This will be achieved through the report’s unique analysis of both the market and company’s competitors, and by providing detailed information about the internal and external factors that affect the relevant industry.
• Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• The report will help you to find prospective partners and suppliers.
• The annual profitability data provided in the report will assist and strengthen your company’s decision-making processes.

About Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan. The company’s drugs are marketed in approximately 90 countries worldwide.

The company has an international marketing network, including Japan and 13 overseas bases in the U.S., Europe, and Asia. From these bases, the company markets its original products, such as the anti-prostatic cancer agent leuprolide acetate (marketed as Lupron Depot, Enantone, Prostap, and Leuplin), the anti-peptic ulcer agent lansoprazole (marketed as Prevacid, Ogast, Takepron, and other names), the anti-hypertensive agent candesartan cilexetil (marketed as Blopress, Kenzen, and Amias), and the anti-diabetic agent pioglitazone hydrochloride (marketed as Actos).

Segments

The company operates its business in two categories, Pharmaceutical business and Other businesses.

The Pharmaceutical business represents the ethical drug business and healthcare business.

Other businesses include business activities involving the production and marketing of a range of products, including vitamin bulks, test reagents & clinical diagnostics, photographic chemicals, and inorganic chemicals.

Products

Candesartan Cilexetil

Candesartan cilexetil is an angiotensin receptor blocker (ARB) that is used in hypertension treatment. Its once-daily dosing provides patients with a mild anti-hypertensive action. In addition, candesartan cilexetil is also applied for the treatment of chronic heart failure.

Pioglitazone Hydrochloride

Once-daily dosing with pioglitazone hydrochloride improves insulin sensitivity and reduces blood glucose levels, without placing any additional burdens on the pancreas. The drug is marketed in approximately 80 countries worldwide. In the United States, Actoplus Met, a fixed-dose combination tablet of pioglitazone hydrochloride and metformin, as well as Duetact, a fixed-dose combination tablet of pioglitazone hydrochloride and glimepiride, are also marketed.

Strategic Partnerships

The company, in September 2007, entered into partnership with H. Lundbeck A/S for the development and commercialization of Lundbeck's portfolio of compounds, Lu AA21004, for the treatment of mood and anxiety disorders and entering Phase III studies in December 2007. This belongs to a new chemical class, with an active mechanism that differs from antidepressants.

In November 2009, Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. announced that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications. The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide, which are compounds currently in phase 2 development for treatment of obesity.

In January 2009, Seattle Genetics Inc. and Takeda Oncology with its parent company Takeda Pharmaceutical Co. Ltd. entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35).

History

Takeda Pharmaceutical Company Limited was founded in 1781.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. TAKEDA PHARMACEUTICAL CO. LTD. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. TAKEDA PHARMACEUTICAL CO. LTD. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. TAKEDA PHARMACEUTICAL CO. LTD. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. TAKEDA PHARMACEUTICAL CO. LTD. FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. TAKEDA PHARMACEUTICAL CO. LTD. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Takeda Pharmaceutical Co. Ltd. Direct Competitors
5.2. Comparison of Takeda Pharmaceutical Co. Ltd. and Direct Competitors Financial Ratios
5.3. Comparison of Takeda Pharmaceutical Co. Ltd. and Direct Competitors Stock Charts
5.4. Takeda Pharmaceutical Co. Ltd. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Takeda Pharmaceutical Co. Ltd. Industry Position Analysis

6. TAKEDA PHARMACEUTICAL CO. LTD. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. TAKEDA PHARMACEUTICAL CO. LTD. EXPERTS REVIEW

7.1. Experts Opinion
7.2. Experts Estimates

APPENDIX 1: RATIO DEFINITIONS

LIST OF TABLES

Table 1. Takeda Pharmaceutical Co. Ltd. Key Facts
Table 2. Takeda Pharmaceutical Co. Ltd. Profitability
Table 3. Takeda Pharmaceutical Co. Ltd. Management Effectiveness
Table 4. Takeda Pharmaceutical Co. Ltd. Income Statement Key Figures
Table 5. Takeda Pharmaceutical Co. Ltd. Balance Sheet Key Figures
Table 6. Takeda Pharmaceutical Co. Ltd. Cash Flow Statement Key Figures
Table 7. Financial Performance Abbreviation Guide
Table 8. Takeda Pharmaceutical Co. Ltd. Key Executives
Table 9. Takeda Pharmaceutical Co. Ltd. Key Executives Biographies *
Table 10. Takeda Pharmaceutical Co. Ltd. Key Executives Compensations *
Table 11. Takeda Pharmaceutical Co. Ltd. Key Executives Stock Options *
Table 12. Takeda Pharmaceutical Co. Ltd. Major Shareholders
Table 13. Takeda Pharmaceutical Co. Ltd. History
Table 14. Takeda Pharmaceutical Co. Ltd. Products
Table 15. Takeda Pharmaceutical Co. Ltd. Revenues by Product
Table 16. Takeda Pharmaceutical Co. Ltd. Revenues by Region
Table 17. Takeda Pharmaceutical Co. Ltd. Offices and Representations
Table 18. Takeda Pharmaceutical Co. Ltd. SWOT Analysis
Table 19. Takeda Pharmaceutical Co. Ltd. Income Statement 2008-2011 Including 4-years Trends
Table 20. Takeda Pharmaceutical Co. Ltd. Income Statement Latest 4 Quarters Including Trends
Table 21. Takeda Pharmaceutical Co. Ltd. Balance Sheet 2008-2011 Including Trends
Table 22. Takeda Pharmaceutical Co. Ltd. Balance Sheet Latest 4 Quarters Including Trends
Table 23. Takeda Pharmaceutical Co. Ltd. Cash Flow 2008-2011 Including Trends
Table 24. Takeda Pharmaceutical Co. Ltd. Cash Flow Latest 4 Quarters Including Trends
Table 25. Takeda Pharmaceutical Co. Ltd. Profitability Ratios
Table 26. Takeda Pharmaceutical Co. Ltd. Margin Analysis Ratios
Table 27. Takeda Pharmaceutical Co. Ltd. Asset Turnover Ratios
Table 28. Takeda Pharmaceutical Co. Ltd. Credit Ratios
Table 29. Takeda Pharmaceutical Co. Ltd. Long-Term Solvency Ratios
Table 30. Takeda Pharmaceutical Co. Ltd. Financial Ratios Growth Over Prior Year
Table 31. Takeda Pharmaceutical Co. Ltd. Capital Market Snapshot
Table 32. Takeda Pharmaceutical Co. Ltd. Direct Competitors Key Facts
Table 33. Takeda Pharmaceutical Co. Ltd. Direct Competitors Profitability Ratios
Table 34. Takeda Pharmaceutical Co. Ltd. Direct Competitors Margin Analysis Ratios
Table 35. Takeda Pharmaceutical Co. Ltd. Direct Competitors Asset Turnover Ratios
Table 36. Takeda Pharmaceutical Co. Ltd. Direct Competitors Credit Ratios
Table 37. Takeda Pharmaceutical Co. Ltd. Direct Competitors Long-Term Solvency Ratios
Table 38. Pharmaceuticals and Biotechnology Industry Statistics
Table 39. Takeda Pharmaceutical Co. Ltd. Industry Position
Table 40. Takeda Pharmaceutical Co. Ltd. vs. Industry Income Statement Analysis
Table 41. Takeda Pharmaceutical Co. Ltd. vs. Industry Balance Sheet Analysis
Table 42. Takeda Pharmaceutical Co. Ltd. vs. Industry Cash Flow Analysis
Table 43. Takeda Pharmaceutical Co. Ltd. vs. Industry Ratios Comparison
Table 44. Takeda Pharmaceutical Co. Ltd. Consensus Recommendations*
Table 45. Takeda Pharmaceutical Co. Ltd. Analyst Recommendation Summary*
Table 46. Takeda Pharmaceutical Co. Ltd. Price Target Summary*
Table 47. Takeda Pharmaceutical Co. Ltd. Experts Recommendation Trends*
Table 48. Takeda Pharmaceutical Co. Ltd. Revenue Estimates Analysis*
Table 49. Takeda Pharmaceutical Co. Ltd. Earnings Estimates Analysis*
Table 50. Takeda Pharmaceutical Co. Ltd. Historical Surprises*
Table 51. Takeda Pharmaceutical Co. Ltd. Revenue Estimates Trend*
Table 52. Takeda Pharmaceutical Co. Ltd. Earnings Estimates Trend*
Table 53. Takeda Pharmaceutical Co. Ltd. Revenue Revisions*
Table 54. Takeda Pharmaceutical Co. Ltd. Earnings Revisions*

LIST OF FIGURES

Figure 1. Takeda Pharmaceutical Co. Ltd. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Figure 2. Takeda Pharmaceutical Co. Ltd. Profit Margin Chart
Figure 3. Takeda Pharmaceutical Co. Ltd. Operating Margin Chart
Figure 4. Takeda Pharmaceutical Co. Ltd. Return on Equity (ROE) Chart
Figure 5. Takeda Pharmaceutical Co. Ltd. Return on Assets (ROA) Chart
Figure 6. Takeda Pharmaceutical Co. Ltd. Debt to Equity Chart
Figure 7. Takeda Pharmaceutical Co. Ltd. Current Ratio Chart
Figure 8. Takeda Pharmaceutical Co. Ltd. 1-year Stock Charts
Figure 9. Takeda Pharmaceutical Co. Ltd. 5-year Stock Charts
Figure 10. Takeda Pharmaceutical Co. Ltd. vs. Main Indexes 1-year Stock Chart
Figure 11. Takeda Pharmaceutical Co. Ltd. vs. Direct Competitors 1-year Stock Charts
Figure 12. Takeda Pharmaceutical Co. Ltd. Article Density Chart

* – Data availability depends on company’s security policy.
The complete financial data is available for public traded companies.

The above Company Fundamental Report is a half-ready report.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get up-to-date version for the same price.